Position in URGN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$18,396,398
-$4,148,255 QoQ
Shares Held
1,023,159
+6.3% QoQ
Ownership
2.10%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2023
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in URGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026D. E. Shaw & Co., Inc. holds $4,382,181,502 across 180 Biotechnology names. URGN ranks #44 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INSM |
INSMED Inc
|
5,625,825 | $919,934,903 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
1,059,062 | $350,411,843 | |
| 3 | BBIO |
BridgeBio Pharma, Inc.
|
2,545,486 | $189,027,789 | |
| 4 | PCVX |
Vaxcyte, Inc.
|
2,865,318 | $166,503,628 | |
| 5 | EXEL |
Exelixis, Inc.
|
3,603,063 | $154,535,371 | |
| 6 | HALO |
Halozyme Therapeutics, Inc.
|
1,868,708 | $120,774,597 | |
| 7 | PTCT |
Ptc Therapeutics, Inc.
|
1,640,381 | $111,759,157 | |
| 8 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
248,960 | $111,170,598 |
All Filings in URGN
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $18,396,398 | 1,023,159 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $22,544,653 | 962,624 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $17,734,213 | 888,933 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $375,818 | 27,432 | Shares | Defined | 2025-08-14 | |
| 2024-06-30 | $181,945 | 10,843 | Shares | Defined | 2024-08-14 | |
| 2023-12-31 | $1,168,095 | 77,873 | Shares | Defined | 2024-02-14 | |
| 2023-09-30 | $471,198 | 33,633 | Shares | Defined | 2023-11-14 | |
| No filing history on record for this holder in this stock. | ||||||